Clinical Trials
16 trialsNCT06353386 2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05848011 2026-05-22
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
MacroGenics
Phase 2 Completed
NCT06863272 2026-05-15
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07587814 2026-05-14
COCORIVO
Centre Henri Becquerel
Phase NA Not yet recruiting
NCT03431350 2026-05-11
QUEST
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT07225946 2026-05-11
KLK2-PASenger
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT02592317 2026-05-08
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 1 Active not recruiting
NCT03748641 2026-05-08
MAGNITUDE
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06788509 2026-05-08
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Phase 1 Enrolling by invitation
NCT04868604 2026-05-06
SECuRE
Clarity Pharmaceuticals Ltd
Phase 1/2 Recruiting
NCT07047118 2026-05-01
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Phase 2 Active not recruiting
NCT04597411 2026-04-30
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
Phase 1 Active not recruiting
NCT05997615 2026-04-20
AMX-500
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT04337580 2026-04-13
FASN
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT06190899 2026-04-13
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Celcuity Inc
Phase 1/2 Recruiting
NCT07258407 2026-03-16
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
T.O.A.D. Oncology SA
Phase 1/2 Recruiting